ArticleTherapeutic advances in medical oncology2020
Observational cohort study of clinical outcome in Epstein-Barr virus associated gastric cancer patients.
Article in Therapeutic advances in medical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 29 citations in OpenAlex.
- Neoadjuvant toripalimab plus CapeOX in locally advanced Epstein-Barr virus-associated gastric or gastroesophageal junction adenocarcinoma: a phase Ⅱ trial.Nature communications · 2026Trial
- An EBNA1-YAP signaling axis drives immune escape through CD276 in EBV-associated gastric cancer.Cell death & disease · 2025Article
- 2-Deoxyglucose as a therapeutic strategy for EBV-associated gastric carcinoma: Glycolytic and lytic reactivation inhibition under hypoxic conditions.Journal of virus eradication · 2025Article
- T-betNature communications · 2025Article
- Demographic/clinicopathological characteristics and prognosis of resectable Epstein-Barr virus-associated gastric cancer: a nested case-control study from an Eastern China.Frontiers in oncology · 2025Article
- Therapeutic opportunities in EBV-positive gastric cancer subtypes.Therapeutic advances in medical oncology · 2025Review
- Classical biomarkers and non-coding RNAs associated with diagnosis and treatment in gastric cancer.Oncology research · 2025Review
- Unlocking the Potential: Epstein-Barr Virus (EBV) in Gastric Cancer and Future Treatment Prospects, a Literature Review.Pathogens (Basel, Switzerland) · 2024Review
- Immune Landscape of Epstein-Barr Virus-Associated Gastric Cancer: Analysis From a Western Academic Institution.The Journal of surgical research · 2024Article
- Revealing the secret behind Epstein-Barr virus-specific tumor immune contexture.Cancer communications (London, England) · 2024Article
- The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023.Cancer communications (London, England) · 2024Article
- Case report: A case of rare metastasis of gastric cancer to the axillary lymph node metastasis treated with combination immunotherapy.Frontiers in immunology · 2024Article
- Dynamic single-cell mapping unveils Epstein‒Barr virus-imprinted T-cell exhaustion and on-treatment response.Signal transduction and targeted therapy · 2023Article
- Assessing Epstein-Barr virus in gastric cancer: clinicopathological features and prognostic implications.Infectious agents and cancer · 2023Article
- A potential EBV-related classifier is associated with the efficacy of immunotherapy in gastric cancer.Translational cancer research · 2022Article
- Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.Journal for immunotherapy of cancer · 2022Article
- Circulating Epstein-Barr virus DNA associated with hepatic impairment and its diagnostic and prognostic role in patients with gastric cancer.Frontiers in medicine · 2022Article
- Baseline splenic volume as a biomarker for clinical outcome and circulating lymphocyte count in gastric cancer.Frontiers in oncology · 2022Article
- Impact of mature tertiary lymphoid structures on prognosis and therapeutic response of Epstein-Barr virus-associated gastric cancer patients.Frontiers in immunology · 2022Article
- EBV-associated diseases: Current therapeutics and emerging technologies.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpstein-Barr virus-associated gastric cancer (EBVaGC) has unique clinicopathologic features and our present understanding of its treatment outcome is limited. Here, we investigated the clinical outcomes of resectable and metastatic EBVaGC cases with regards to their respective treatment.
methodsWe retrieved the data of EBVaGC patients treated at our center from October 2014 to June 2019. The primary endpoint was overall survival (OS). Secondary endpoints were disease-free survival (DFS) for stage I-III patients, progression-free survival (PFS) and objective response rate (ORR) for stage IV patients.
resultsPatients classified as stage I-III accounted for 83.7% of the total 197 cases analyzed. Two patients had mismatched repair-deficiency. The 5-year OS rate of the entire cohort was 63.51% [95% (confidence interval (CI): 52.31-72.76%]. Tumor-node-metastasis (TNM) stage and gastric stump cancer were identified as independent prognostic factors for OS. The 3- and 5-year DFS rate for stage I-III patients were 83.72% (95% CI: 75.86-89.19%) and 73.83% (95% CI: 60.39-83.32%), respectively. TNM stage III, neural invasion, lymphovascular invasion, and baseline plasma EBV-DNA positive were correlated with shorter DFS. The ORR and disease control rate (DCR) for metastatic EBVaGC patients to first-line therapy were 29.0% and 90.3% (median PFS: 9.8 months), respectively, and to second-line therapy were 25.0% and 75.0%, respectively. Seven patients received anti-PD1 therapy and had an ORR of 28.5% and a median PFS of 2.8 months.
conclusionsEBVaGC patients have few metastases, long DFS, and high DCR. TNM stage and gastric stump cancer were independent prognostic factors for OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.